[{"polarity": ["false"], "orig_sen": "In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. ", "drug2": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "drug1": "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"}, {"polarity": ["false", "false", "false"], "orig_sen": "Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ", "drug2": "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine", "drug1": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"}, {"polarity": ["false", "false", "false"], "orig_sen": "Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ", "drug2": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "drug1": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"}, {"polarity": ["false", "false", "false"], "orig_sen": "Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ", "drug2": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "drug1": "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"}, {"polarity": ["false"], "orig_sen": "Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). ", "drug2": "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine", "drug1": "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"}, {"polarity": ["false", "false", "false"], "orig_sen": "After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. ", "drug2": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "drug1": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"}, {"polarity": ["false", "false", "true"], "orig_sen": "After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. ", "drug2": "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine", "drug1": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"}, {"polarity": ["true"], "orig_sen": "These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. ", "drug2": "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine", "drug1": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"}, {"polarity": ["false"], "orig_sen": "These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. ", "drug2": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "drug1": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"}, {"polarity": ["false"], "orig_sen": "These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. ", "drug2": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "drug1": "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"}, {"polarity": ["true"], "orig_sen": "The 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine treatment also had a significant effect on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups. ", "drug2": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "drug1": "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"}, {"polarity": ["false"], "orig_sen": "In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. ", "drug2": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "drug1": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"}, {"polarity": ["false", "true"], "orig_sen": "In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. ", "drug2": "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine", "drug1": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"}, {"polarity": ["true"], "orig_sen": "Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, significantly reduces 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity towards dopaminergic and noradrenergic cell groups in non-human primates. ", "drug2": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "drug1": "3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"}, {"polarity": ["false"], "orig_sen": "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.\r\n", "drug2": "panobinostat", "drug1": "ketoconazole"}, {"polarity": ["false"], "orig_sen": "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.\r\n", "drug2": "LBH589", "drug1": "ketoconazole"}, {"polarity": ["false"], "orig_sen": "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.\r\n", "drug2": "histone deacetylase inhibitor", "drug1": "ketoconazole"}, {"polarity": ["false"], "orig_sen": "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.\r\n", "drug2": "LBH589", "drug1": "panobinostat"}, {"polarity": ["false"], "orig_sen": "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.\r\n", "drug2": "histone deacetylase inhibitor", "drug1": "panobinostat"}, {"polarity": ["false"], "orig_sen": "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.\r\n", "drug2": "histone deacetylase inhibitor", "drug1": "LBH589"}, {"polarity": ["false"], "orig_sen": "This study evaluated the effect of a potent CYP3A inhibitor, ketoconazole, on the pharmacokinetics and safety of panobinostat.", "drug2": "panobinostat", "drug1": "ketoconazole"}, {"polarity": ["false"], "orig_sen": "On day 8, a single panobinostat dose was co-administered with ketoconazole. ", "drug2": "ketoconazole", "drug1": "panobinostat"}, {"polarity": ["true"], "orig_sen": "In the presence of ketoconazole, there was 1.6- and 1.8-fold increase in C (max) and AUC of panobinostat, respectively. ", "drug2": "panobinostat", "drug1": "ketoconazole"}, {"polarity": ["false"], "orig_sen": "Co-administration of panobinostat with CYP3A inhibitors is feasible as the observed increase in panobinostat PK parameters was not considered clinically relevant. ", "drug2": "panobinostat", "drug1": "panobinostat"}, {"polarity": ["false"], "orig_sen": "Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of panobinostat was not studied with CYP3A inhibitors, close monitoring of panobinostat-related adverse events is necessary.", "drug2": "panobinostat", "drug1": "panobinostat"}, {"polarity": ["false"], "orig_sen": "Interaction study of moxifloxacin and lomefloxacin with co-administered drugs.\n", "drug2": "lomefloxacin", "drug1": "moxifloxacin"}, {"polarity": ["false"], "orig_sen": "Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. ", "drug2": "lomefloxacin", "drug1": "Moxifloxacin"}, {"polarity": ["false"], "orig_sen": "Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. ", "drug2": "fluoroquinolone antibiotics", "drug1": "Moxifloxacin"}, {"polarity": ["false"], "orig_sen": "Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. ", "drug2": "fluoroquinolone antibiotics", "drug1": "lomefloxacin"}, {"polarity": ["false"], "orig_sen": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "drug2": "fluoroquinolones", "drug1": "moxifloxacin"}, {"polarity": ["false"], "orig_sen": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "drug2": "sucralfate", "drug1": "moxifloxacin"}, {"polarity": ["false"], "orig_sen": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "drug2": "gelusil", "drug1": "moxifloxacin"}, {"polarity": ["false"], "orig_sen": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "drug2": "erythromycin", "drug1": "moxifloxacin"}, {"polarity": ["false"], "orig_sen": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "drug2": "multi minerals", "drug1": "moxifloxacin"}, {"polarity": ["false"], "orig_sen": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "drug2": "sucralfate", "drug1": "fluoroquinolones"}, {"polarity": ["false"], "orig_sen": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "drug2": "gelusil", "drug1": "fluoroquinolones"}, {"polarity": ["false"], "orig_sen": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "drug2": "erythromycin", "drug1": "fluoroquinolones"}, {"polarity": ["false"], "orig_sen": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "drug2": "multi minerals", "drug1": "fluoroquinolones"}, {"polarity": ["false"], "orig_sen": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "drug2": "gelusil", "drug1": "sucralfate"}, {"polarity": ["false"], "orig_sen": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "drug2": "erythromycin", "drug1": "sucralfate"}, {"polarity": ["false"], "orig_sen": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "drug2": "multi minerals", "drug1": "sucralfate"}, {"polarity": ["false"], "orig_sen": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "drug2": "erythromycin", "drug1": "gelusil"}, {"polarity": ["false"], "orig_sen": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "drug2": "multi minerals", "drug1": "gelusil"}, {"polarity": ["false"], "orig_sen": "Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ", "drug2": "multi minerals", "drug1": "erythromycin"}, {"polarity": ["false"], "orig_sen": "The response of moxifloxacin and lomefloxacin after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector. ", "drug2": "lomefloxacin", "drug1": "moxifloxacin"}, {"polarity": ["false"], "orig_sen": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug2": "Lomefloxacin", "drug1": "Moxifloxacin"}, {"polarity": ["true"], "orig_sen": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug2": "sucralfate", "drug1": "Moxifloxacin"}, {"polarity": ["true"], "orig_sen": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug2": "gelusil", "drug1": "Moxifloxacin"}, {"polarity": ["true"], "orig_sen": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug2": "erythromycin", "drug1": "Moxifloxacin"}, {"polarity": ["true"], "orig_sen": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug2": "multi-minerals", "drug1": "Moxifloxacin"}, {"polarity": ["true"], "orig_sen": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug2": "sucralfate", "drug1": "Lomefloxacin"}, {"polarity": ["true"], "orig_sen": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug2": "gelusil", "drug1": "Lomefloxacin"}, {"polarity": ["true"], "orig_sen": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug2": "erythromycin", "drug1": "Lomefloxacin"}, {"polarity": ["true"], "orig_sen": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug2": "multi-minerals", "drug1": "Lomefloxacin"}, {"polarity": ["false"], "orig_sen": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug2": "gelusil", "drug1": "sucralfate"}, {"polarity": ["false"], "orig_sen": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug2": "erythromycin", "drug1": "sucralfate"}, {"polarity": ["false"], "orig_sen": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug2": "multi-minerals", "drug1": "sucralfate"}, {"polarity": ["false"], "orig_sen": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug2": "erythromycin", "drug1": "gelusil"}, {"polarity": ["false"], "orig_sen": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug2": "multi-minerals", "drug1": "gelusil"}, {"polarity": ["false"], "orig_sen": "Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ", "drug2": "multi-minerals", "drug1": "erythromycin"}, {"polarity": ["false"], "orig_sen": "Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.\r\n", "drug2": "itraconazole", "drug1": "S-ketamine"}, {"polarity": ["true"], "orig_sen": "Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.\r\n", "drug2": "ticlopidine", "drug1": "S-ketamine"}, {"polarity": ["false"], "orig_sen": "Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.\r\n", "drug2": "ticlopidine", "drug1": "itraconazole"}, {"polarity": ["false"], "orig_sen": "This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. ", "drug2": "ticlopidine", "drug1": "S-ketamine"}, {"polarity": ["false"], "orig_sen": "This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. ", "drug2": "itraconazole", "drug1": "S-ketamine"}, {"polarity": ["false"], "orig_sen": "This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. ", "drug2": "itraconazole", "drug1": "ticlopidine"}, {"polarity": ["false"], "orig_sen": "In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ", "drug2": "ticlopidine", "drug1": "S-ketamine"}, {"polarity": ["false"], "orig_sen": "In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ", "drug2": "itraconazole", "drug1": "S-ketamine"}, {"polarity": ["false"], "orig_sen": "In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ", "drug2": "itraconazole", "drug1": "ticlopidine"}, {"polarity": ["true"], "orig_sen": "Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ", "drug2": "ketamine", "drug1": "Ticlopidine"}, {"polarity": ["false"], "orig_sen": "Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ", "drug2": "itraconazole", "drug1": "Ticlopidine"}, {"polarity": ["false"], "orig_sen": "Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ", "drug2": "S-ketamine", "drug1": "Ticlopidine"}, {"polarity": ["false"], "orig_sen": "Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ", "drug2": "itraconazole", "drug1": "ketamine"}, {"polarity": ["false"], "orig_sen": "Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ", "drug2": "S-ketamine", "drug1": "ketamine"}, {"polarity": ["false"], "orig_sen": "Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ", "drug2": "S-ketamine", "drug1": "itraconazole"}, {"polarity": ["false"], "orig_sen": "The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ", "drug2": "ketamine", "drug1": "norketamine"}, {"polarity": ["false"], "orig_sen": "The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ", "drug2": "ticlopidine", "drug1": "norketamine"}, {"polarity": ["false"], "orig_sen": "The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ", "drug2": "itraconazole", "drug1": "norketamine"}, {"polarity": ["false"], "orig_sen": "The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ", "drug2": "ticlopidine", "drug1": "ketamine"}, {"polarity": ["false"], "orig_sen": "The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ", "drug2": "itraconazole", "drug1": "ketamine"}, {"polarity": ["false"], "orig_sen": "The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ", "drug2": "itraconazole", "drug1": "ticlopidine"}, {"polarity": ["false"], "orig_sen": "In the ticlopidine and itraconazole phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05). ", "drug2": "itraconazole", "drug1": "ticlopidine"}, {"polarity": ["true"], "orig_sen": "The findings suggest that the dosage of S-ketamine should be reduced in patients receiving ticlopidine.", "drug2": "ticlopidine", "drug1": "S-ketamine"}, {"polarity": ["false"], "orig_sen": "The 3-Deazaneplanocin A (DZNep), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia. ", "drug2": "DZNep", "drug1": "3-Deazaneplanocin A"}, {"polarity": ["false", "false", "false"], "orig_sen": "We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ", "drug2": "DZNep", "drug1": "DZNep"}, {"polarity": ["false", "true"], "orig_sen": "We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ", "drug2": "ABT-737", "drug1": "DZNep"}, {"polarity": ["false"], "orig_sen": "We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ", "drug2": "DZNep", "drug1": "ABT-737"}, {"polarity": ["false"], "orig_sen": "In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. ", "drug2": "ABT-737", "drug1": "DZNep"}, {"polarity": ["false"], "orig_sen": "In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. ", "drug2": "DZNep", "drug1": "DZNep"}, {"polarity": ["true"], "orig_sen": "In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. ", "drug2": "DZNep", "drug1": "ABT-737"}, {"polarity": ["true"], "orig_sen": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "drug2": "antiretroviral", "drug1": "Implanon"}, {"polarity": ["true"], "orig_sen": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "drug2": "Implanon", "drug1": "antiretroviral"}, {"polarity": ["false"], "orig_sen": "Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study.\r\n", "drug2": "warfarin", "drug1": "Antidepressant"}, {"polarity": ["false"], "orig_sen": "We sought to evaluate whether initiation of an antidepressant increases the risk of hospitalization for gastrointestinal bleeding in warfarin users.", "drug2": "warfarin", "drug1": "antidepressant"}, {"polarity": ["false"], "orig_sen": "In total, 430,455 warfarin users contributed 407,370 person-years of warfarin use. ", "drug2": "warfarin", "drug1": "warfarin"}, {"polarity": ["true"], "orig_sen": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ", "drug2": "citalopram", "drug1": "Warfarin"}, {"polarity": ["true"], "orig_sen": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ", "drug2": "fluoxetine", "drug1": "Warfarin"}, {"polarity": ["true"], "orig_sen": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ", "drug2": "paroxetine", "drug1": "Warfarin"}, {"polarity": ["true"], "orig_sen": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ", "drug2": "amitriptyline", "drug1": "Warfarin"}, {"polarity": ["false"], "orig_sen": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ", "drug2": "fluoxetine", "drug1": "citalopram"}, {"polarity": ["false"], "orig_sen": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ", "drug2": "paroxetine", "drug1": "citalopram"}, {"polarity": ["false"], "orig_sen": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ", "drug2": "amitriptyline", "drug1": "citalopram"}, {"polarity": ["false"], "orig_sen": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ", "drug2": "paroxetine", "drug1": "fluoxetine"}, {"polarity": ["false"], "orig_sen": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ", "drug2": "amitriptyline", "drug1": "fluoxetine"}, {"polarity": ["false"], "orig_sen": "Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ", "drug2": "amitriptyline", "drug1": "paroxetine"}, {"polarity": ["true"], "orig_sen": "Also mirtazapine, which is not believed to interact with warfarin, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]). ", "drug2": "warfarin", "drug1": "mirtazapine"}, {"polarity": ["true"], "orig_sen": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug2": "citalopram", "drug1": "Warfarin"}, {"polarity": ["true"], "orig_sen": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug2": "fluoxetine", "drug1": "Warfarin"}, {"polarity": ["true"], "orig_sen": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug2": "paroxetine", "drug1": "Warfarin"}, {"polarity": ["true"], "orig_sen": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug2": "amitriptyline", "drug1": "Warfarin"}, {"polarity": ["true"], "orig_sen": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug2": "mirtazapine", "drug1": "Warfarin"}, {"polarity": ["false"], "orig_sen": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug2": "fluoxetine", "drug1": "citalopram"}, {"polarity": ["false"], "orig_sen": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug2": "paroxetine", "drug1": "citalopram"}, {"polarity": ["false"], "orig_sen": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug2": "amitriptyline", "drug1": "citalopram"}, {"polarity": ["false"], "orig_sen": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug2": "mirtazapine", "drug1": "citalopram"}, {"polarity": ["false"], "orig_sen": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug2": "paroxetine", "drug1": "fluoxetine"}, {"polarity": ["false"], "orig_sen": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug2": "amitriptyline", "drug1": "fluoxetine"}, {"polarity": ["false"], "orig_sen": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug2": "mirtazapine", "drug1": "fluoxetine"}, {"polarity": ["false"], "orig_sen": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug2": "amitriptyline", "drug1": "paroxetine"}, {"polarity": ["false"], "orig_sen": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug2": "mirtazapine", "drug1": "paroxetine"}, {"polarity": ["false"], "orig_sen": "Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ", "drug2": "mirtazapine", "drug1": "amitriptyline"}, {"polarity": ["false"], "orig_sen": "The incubations were performed in the absence and presence of the non-specific CYP inhibitor, 1-aminobenzotriazole (ABT) and isoform-specific inhibitors. ", "drug2": "ABT", "drug1": "1-aminobenzotriazole"}, {"polarity": ["true"], "orig_sen": "ABT decreased the toxicity of precocene I, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner. ", "drug2": "precocene I", "drug1": "ABT"}, {"polarity": ["false"], "orig_sen": "Of the isoform-specific CYP inhibitors tested for an effect on the precocene I metabolite profile, only tranylcypromine was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1. ", "drug2": "tranylcypromine", "drug1": "precocene I"}, {"polarity": ["false"], "orig_sen": "With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ", "drug2": "diethyldithiocarbamate", "drug1": "ABT"}, {"polarity": ["false"], "orig_sen": "With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ", "drug2": "tranylcypromine", "drug1": "ABT"}, {"polarity": ["false"], "orig_sen": "With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ", "drug2": "ketoconazole", "drug1": "ABT"}, {"polarity": ["false"], "orig_sen": "With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ", "drug2": "tranylcypromine", "drug1": "diethyldithiocarbamate"}, {"polarity": ["false"], "orig_sen": "With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ", "drug2": "ketoconazole", "drug1": "diethyldithiocarbamate"}, {"polarity": ["false"], "orig_sen": "With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ", "drug2": "ketoconazole", "drug1": "tranylcypromine"}, {"polarity": ["false"], "orig_sen": "Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ", "drug2": "sulfaphenazole", "drug1": "Furafylline"}, {"polarity": ["false"], "orig_sen": "Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ", "drug2": "quinidine", "drug1": "Furafylline"}, {"polarity": ["false"], "orig_sen": "Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ", "drug2": "precocene I", "drug1": "Furafylline"}, {"polarity": ["false"], "orig_sen": "Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ", "drug2": "quinidine", "drug1": "sulfaphenazole"}, {"polarity": ["false"], "orig_sen": "Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ", "drug2": "precocene I", "drug1": "sulfaphenazole"}, {"polarity": ["true"], "orig_sen": "Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ", "drug2": "precocene I", "drug1": "quinidine"}, {"polarity": ["false"], "orig_sen": "These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of precocene I and therefore may not be an appropriate model for precocene I metabolism. ", "drug2": "precocene I", "drug1": "precocene I"}, {"polarity": ["false"], "orig_sen": "To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of adeno-associated virus-2 (AAV2).", "drug2": "AAV2", "drug1": "adeno-associated virus-2"}, {"polarity": ["false"], "orig_sen": "AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ", "drug2": "collagenase", "drug1": "AAV2"}, {"polarity": ["false"], "orig_sen": "AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ", "drug2": "hyaluronan lyase", "drug1": "AAV2"}, {"polarity": ["false"], "orig_sen": "AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ", "drug2": "heparinase III", "drug1": "AAV2"}, {"polarity": ["false"], "orig_sen": "AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ", "drug2": "chondroitin ABC lyase", "drug1": "AAV2"}, {"polarity": ["false"], "orig_sen": "AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ", "drug2": "hyaluronan lyase", "drug1": "collagenase"}, {"polarity": ["false"], "orig_sen": "AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ", "drug2": "heparinase III", "drug1": "collagenase"}, {"polarity": ["false"], "orig_sen": "AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ", "drug2": "chondroitin ABC lyase", "drug1": "collagenase"}, {"polarity": ["false"], "orig_sen": "AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ", "drug2": "heparinase III", "drug1": "hyaluronan lyase"}, {"polarity": ["false"], "orig_sen": "AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ", "drug2": "chondroitin ABC lyase", "drug1": "hyaluronan lyase"}, {"polarity": ["false"], "orig_sen": "AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ", "drug2": "chondroitin ABC lyase", "drug1": "heparinase III"}, {"polarity": ["false"], "orig_sen": "The addition of heparinase III or chondroitin ABC lyase greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina. ", "drug2": "chondroitin ABC lyase", "drug1": "heparinase III"}, {"polarity": ["false"], "orig_sen": "Hyaluronan lyase had a limited effect and collagenase was ineffective. ", "drug2": "collagenase", "drug1": "Hyaluronan lyase"}, {"polarity": ["false"], "orig_sen": "Electroretinograms survived with higher concentrations of heparinase III and chondroitin ABC lyase than were required for optimal retinal transduction. ", "drug2": "chondroitin ABC lyase", "drug1": "heparinase III"}, {"polarity": ["true"], "orig_sen": "AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. ", "drug2": "heparinase III", "drug1": "AAV2"}, {"polarity": ["true"], "orig_sen": "AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. ", "drug2": "chondroitin ABC lyase", "drug1": "AAV2"}, {"polarity": ["false"], "orig_sen": "AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. ", "drug2": "chondroitin ABC lyase", "drug1": "heparinase III"}, {"polarity": ["false"], "orig_sen": "Prevention of emergence agitation in seven children receiving low-dose ketamine and propofol total intravenous anesthesia.\r\n", "drug2": "propofol", "drug1": "ketamine"}, {"polarity": ["false"], "orig_sen": "We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose ketamine in conjunction with propofol for total intravenous anesthesia (TIVA) repeatedly for radiation therapy. ", "drug2": "propofol", "drug1": "ketamine"}, {"polarity": ["false"], "orig_sen": "EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. ", "drug2": "ketamine", "drug1": "propofol"}, {"polarity": ["false"], "orig_sen": "EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. ", "drug2": "propofol", "drug1": "propofol"}, {"polarity": ["false"], "orig_sen": "EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. ", "drug2": "propofol", "drug1": "ketamine"}, {"polarity": ["true", "false"], "orig_sen": "Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.", "drug2": "propofol", "drug1": "ketamine"}, {"polarity": ["false"], "orig_sen": "Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.", "drug2": "propofol", "drug1": "propofol"}, {"polarity": ["false"], "orig_sen": "Tamoxifen, an estrogen antagonist, is the standard hormone treatment for breast cancer. ", "drug2": "estrogen antagonist", "drug1": "Tamoxifen"}, {"polarity": ["false"], "orig_sen": "Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. ", "drug2": "fluoxetine", "drug1": "Paroxetine"}, {"polarity": ["true"], "orig_sen": "Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. ", "drug2": "endoxifen", "drug1": "Paroxetine"}, {"polarity": ["true"], "orig_sen": "Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. ", "drug2": "endoxifen", "drug1": "fluoxetine"}, {"polarity": ["true"], "orig_sen": "It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ", "drug2": "SSRI antidepressants", "drug1": "tamoxifen"}, {"polarity": ["true"], "orig_sen": "It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ", "drug2": "paroxetine", "drug1": "tamoxifen"}, {"polarity": ["true"], "orig_sen": "It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ", "drug2": "fluoxetine", "drug1": "tamoxifen"}, {"polarity": ["false"], "orig_sen": "It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ", "drug2": "paroxetine", "drug1": "SSRI antidepressants"}, {"polarity": ["false"], "orig_sen": "It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ", "drug2": "fluoxetine", "drug1": "SSRI antidepressants"}, {"polarity": ["false"], "orig_sen": "It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ", "drug2": "fluoxetine", "drug1": "paroxetine"}, {"polarity": ["false"], "orig_sen": "Depression does not always require antidepressant drug therapy, and antidepressants have no proven preventive impact on hot flushes linked to the menopause. ", "drug2": "antidepressants", "drug1": "antidepressant drug"}, {"polarity": ["true"], "orig_sen": "If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.", "drug2": "tamoxifen", "drug1": "antidepressant"}, {"polarity": ["false"], "orig_sen": "If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.", "drug2": "anastrozole", "drug1": "antidepressant"}, {"polarity": ["false"], "orig_sen": "If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.", "drug2": "anastrozole", "drug1": "tamoxifen"}, {"polarity": ["false"], "orig_sen": "Amphetamine locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with quinpirole.\r\n", "drug2": "quinpirole", "drug1": "Amphetamine"}, {"polarity": ["false"], "orig_sen": "The objective was to analyze the effects of neonatal quinpirole treatment on effects of amphetamine in adolescent rats using locomotor sensitization and conditioned place preference procedures. ", "drug2": "amphetamine", "drug1": "quinpirole"}, {"polarity": ["true", "false", "false"], "orig_sen": "In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ", "drug2": "amphetamine", "drug1": "quinpirole"}, {"polarity": ["false"], "orig_sen": "In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ", "drug2": "quinpirole", "drug1": "quinpirole"}, {"polarity": ["false"], "orig_sen": "In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ", "drug2": "quinpirole", "drug1": "amphetamine"}, {"polarity": ["false"], "orig_sen": "In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ", "drug2": "amphetamine", "drug1": "amphetamine"}, {"polarity": ["false"], "orig_sen": "Male rats demonstrated sensitization to amphetamine, although this was muted compared with female rats, and were unaffected by neonatal quinpirole. ", "drug2": "quinpirole", "drug1": "amphetamine"}, {"polarity": ["false", "false", "false", "false", "false"], "orig_sen": "Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ", "drug2": "amphetamine", "drug1": "quinpirole"}, {"polarity": ["false"], "orig_sen": "Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ", "drug2": "quinpirole", "drug1": "quinpirole"}, {"polarity": ["false"], "orig_sen": "Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ", "drug2": "quinpirole", "drug1": "amphetamine"}, {"polarity": ["false", "false", "false"], "orig_sen": "Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ", "drug2": "amphetamine", "drug1": "amphetamine"}, {"polarity": ["false"], "orig_sen": "In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.\r\n", "drug2": "tacrolimus", "drug1": "cyclosporine"}, {"polarity": ["false"], "orig_sen": "In vitro studies have identified cyclosporine and tacrolimus as CYP3A inhibitors. ", "drug2": "tacrolimus", "drug1": "cyclosporine"}, {"polarity": ["true"], "orig_sen": "Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). ", "drug2": "cyclosporine", "drug1": "midazolam"}, {"polarity": ["false"], "orig_sen": "Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). ", "drug2": "tacrolimus", "drug1": "midazolam"}, {"polarity": ["false"], "orig_sen": "Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). ", "drug2": "tacrolimus", "drug1": "cyclosporine"}, {"polarity": ["false"], "orig_sen": "The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). ", "drug2": "tacrolimus", "drug1": "midazolam"}, {"polarity": ["false"], "orig_sen": "The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). ", "drug2": "calcineurin inhibitor", "drug1": "midazolam"}, {"polarity": ["false"], "orig_sen": "The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). ", "drug2": "calcineurin inhibitor", "drug1": "tacrolimus"}, {"polarity": ["false"], "orig_sen": "This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. ", "drug2": "tacrolimus", "drug1": "cyclosporine"}, {"polarity": ["false"], "orig_sen": "This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. ", "drug2": "cyclosporine", "drug1": "cyclosporine"}, {"polarity": ["false"], "orig_sen": "This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. ", "drug2": "cyclosporine", "drug1": "tacrolimus"}, {"polarity": ["false"], "orig_sen": "Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.\r\n", "drug2": "darbepoetin", "drug1": "cinacalcet"}, {"polarity": ["false"], "orig_sen": "Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to erythropoietin (EPO) resistance. ", "drug2": "EPO", "drug1": "erythropoietin"}, {"polarity": ["false"], "orig_sen": "Medical treatment with cinacalcet is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on darbepoetin dosing is unknown. ", "drug2": "darbepoetin", "drug1": "cinacalcet"}, {"polarity": ["false"], "orig_sen": "The primary objective of the study was to ascertain the difference in darbepoetin responsiveness before and after 12 months of cinacalcet therapy. ", "drug2": "cinacalcet", "drug1": "darbepoetin"}, {"polarity": ["true"], "orig_sen": "Reduction of PTH by cinacalcet is associated with a decrease in darbepoetin requirement. ", "drug2": "darbepoetin", "drug1": "cinacalcet"}, {"polarity": ["true"], "orig_sen": "Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.\r\n", "drug2": "anti-cancer drugs", "drug1": "celecoxib"}, {"polarity": ["false"], "orig_sen": "This study investigates the ability of cyclooxygenase-2 inhibitors to sensitize cells from different origins to several chemotherapeutic agents. ", "drug2": "chemotherapeutic agents", "drug1": "cyclooxygenase-2 inhibitors"}, {"polarity": ["false"], "orig_sen": "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.", "drug2": "cisplatin", "drug1": "5-FU"}, {"polarity": ["false"], "orig_sen": "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.", "drug2": "doxorubicin", "drug1": "5-FU"}, {"polarity": ["false"], "orig_sen": "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.", "drug2": "etoposide", "drug1": "5-FU"}, {"polarity": ["false"], "orig_sen": "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.", "drug2": "celecoxib", "drug1": "5-FU"}, {"polarity": ["false"], "orig_sen": "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.", "drug2": "doxorubicin", "drug1": "cisplatin"}, {"polarity": ["false"], "orig_sen": "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.", "drug2": "etoposide", "drug1": "cisplatin"}, {"polarity": ["false"], "orig_sen": "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.", "drug2": "celecoxib", "drug1": "cisplatin"}, {"polarity": ["false"], "orig_sen": "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.", "drug2": "etoposide", "drug1": "doxorubicin"}, {"polarity": ["false"], "orig_sen": "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.", "drug2": "celecoxib", "drug1": "doxorubicin"}, {"polarity": ["false"], "orig_sen": "The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.", "drug2": "celecoxib", "drug1": "etoposide"}, {"polarity": ["false"], "orig_sen": "We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. ", "drug2": "celecoxib", "drug1": "celecoxib"}, {"polarity": ["false", "true"], "orig_sen": "We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. ", "drug2": "doxorubicin", "drug1": "celecoxib"}, {"polarity": ["false"], "orig_sen": "These results, if confirmed in-vivo, indicate that celecoxib is not a suitable chemosensitizer for breast cancer or with doxorubicin for other cancers. ", "drug2": "doxorubicin", "drug1": "celecoxib"}, {"polarity": ["false"], "orig_sen": "[Interaction between clopidogrel and proton pump inhibitors].\r\n", "drug2": "proton pump inhibitors", "drug1": "clopidogrel"}, {"polarity": ["false"], "orig_sen": "The drug interaction between proton pump inhibitors and clopidogrel has been the subject of much study in recent years. ", "drug2": "clopidogrel", "drug1": "proton pump inhibitors"}, {"polarity": ["false"], "orig_sen": "Contradictory results regarding the effect of proton pump inhibitors on platelet reactivity and on clinical outcome in clopidogrel-treated patients have been reported in literature. ", "drug2": "clopidogrel", "drug1": "proton pump inhibitors"}, {"polarity": ["true"], "orig_sen": "Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. ", "drug2": "clopidogrel", "drug1": "omeprazole"}, {"polarity": ["false"], "orig_sen": "Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. ", "drug2": "omeprazole", "drug1": "omeprazole"}, {"polarity": ["false"], "orig_sen": "Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. ", "drug2": "omeprazole", "drug1": "clopidogrel"}, {"polarity": ["true"], "orig_sen": "Pantoprazole has a much weaker effect on clopidogrel's pharmacokinetics and on platelet reactivity during concomitant use. ", "drug2": "clopidogrel", "drug1": "Pantoprazole"}, {"polarity": ["false"], "orig_sen": "The influence of the other proton pump inhibitors when used simultaneously with clopidogrel has not yet been investigated in adequately randomized studies. ", "drug2": "clopidogrel", "drug1": "proton pump inhibitors"}, {"polarity": ["true"], "orig_sen": "Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. ", "drug2": "omeprazole", "drug1": "clopidogrel"}, {"polarity": ["true"], "orig_sen": "Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. ", "drug2": "esomeprazole", "drug1": "clopidogrel"}, {"polarity": ["false"], "orig_sen": "Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. ", "drug2": "esomeprazole", "drug1": "omeprazole"}, {"polarity": ["false"], "orig_sen": "To date, there is no conclusive evidence of a clinically-relevant interaction between any of the proton pump inhibitors and clopidogrel.", "drug2": "clopidogrel", "drug1": "proton pump inhibitors"}, {"polarity": ["false"], "orig_sen": "In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.\r\n", "drug2": "fosfomycin", "drug1": "minocycline"}, {"polarity": ["false"], "orig_sen": "In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.\r\n", "drug2": "methicillin", "drug1": "minocycline"}, {"polarity": ["false"], "orig_sen": "In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.\r\n", "drug2": "methicillin", "drug1": "fosfomycin"}, {"polarity": ["false"], "orig_sen": "This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). ", "drug2": "fosfomycin", "drug1": "minocycline"}, {"polarity": ["false"], "orig_sen": "This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). ", "drug2": "methicillin", "drug1": "minocycline"}, {"polarity": ["false"], "orig_sen": "This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). ", "drug2": "methicillin", "drug1": "fosfomycin"}, {"polarity": ["false"], "orig_sen": "The susceptibility results for minocycline and fosfomycin were interpreted according to the most relevant criteria. ", "drug2": "fosfomycin", "drug1": "minocycline"}, {"polarity": ["true"], "orig_sen": "The combination of minocycline and fosfomycin can be synergistic against MRSA. ", "drug2": "fosfomycin", "drug1": "minocycline"}, {"polarity": ["true"], "orig_sen": "The authors report the case of an infant with confirmed congenital hypothyroidism on levothyroxine who experienced a possible drug interaction with simeticone. ", "drug2": "simeticone", "drug1": "levothyroxine"}, {"polarity": ["false"], "orig_sen": "Questioning revealed the child was taking Infacol drops before feeds while on levothyroxine. ", "drug2": "levothyroxine", "drug1": "Infacol"}, {"polarity": ["false"], "orig_sen": "Drug interaction of thyroxine with simeticone has not been reported previously and is not listed in the British National Formulary for Children. ", "drug2": "simeticone", "drug1": "thyroxine"}, {"polarity": ["false"], "orig_sen": "Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.", "drug2": "nonheme iron", "drug1": "Calcium"}, {"polarity": ["false"], "orig_sen": "Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.", "drug2": "heme iron", "drug1": "Calcium"}, {"polarity": ["false"], "orig_sen": "Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.", "drug2": "heme iron", "drug1": "nonheme iron"}, {"polarity": ["true"], "orig_sen": "Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. ", "drug2": "nonheme iron", "drug1": "Calcium"}, {"polarity": ["true"], "orig_sen": "Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. ", "drug2": "heme iron", "drug1": "Calcium"}, {"polarity": ["false"], "orig_sen": "Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. ", "drug2": "heme iron", "drug1": "nonheme iron"}, {"polarity": ["true"], "orig_sen": "However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. ", "drug2": "iron", "drug1": "calcium"}, {"polarity": ["false"], "orig_sen": "However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. ", "drug2": "calcium", "drug1": "calcium"}, {"polarity": ["false"], "orig_sen": "However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. ", "drug2": "calcium", "drug1": "iron"}, {"polarity": ["false"], "orig_sen": "Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. ", "drug2": "nonheme iron", "drug1": "calcium"}, {"polarity": ["false"], "orig_sen": "Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. ", "drug2": "heme iron", "drug1": "calcium"}, {"polarity": ["false"], "orig_sen": "Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. ", "drug2": "heme iron", "drug1": "nonheme iron"}, {"polarity": ["false"], "orig_sen": "We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). ", "drug2": "nonheme iron", "drug1": "calcium"}, {"polarity": ["false"], "orig_sen": "We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). ", "drug2": "ferrous sulfate", "drug1": "calcium"}, {"polarity": ["false"], "orig_sen": "We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). ", "drug2": "ferrous sulfate", "drug1": "nonheme iron"}, {"polarity": ["false"], "orig_sen": "We also evaluated the effects of calcium doses between 200 and 800 mg on absorption of 5 mg heme iron [as concentrated RBC (CRBC)]. ", "drug2": "heme iron", "drug1": "calcium"}, {"polarity": ["false"], "orig_sen": "Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach. ", "drug2": "calcium chloride", "drug1": "Calcium"}, {"polarity": ["false"], "orig_sen": "Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach. ", "drug2": "minerals", "drug1": "Calcium"}, {"polarity": ["false"], "orig_sen": "Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach. ", "drug2": "minerals", "drug1": "calcium chloride"}, {"polarity": ["true"], "orig_sen": "Calcium doses   1000 mg diminished nonheme iron absorption by an average of 49.6%.", "drug2": "nonheme iron", "drug1": "Calcium"}, {"polarity": ["true"], "orig_sen": "A calcium dose of 800 mg diminished absorption of 5 mg heme iron by 37.7%. ", "drug2": "heme iron", "drug1": "calcium"}, {"polarity": ["true"], "orig_sen": "In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. ", "drug2": "nonheme iron", "drug1": "calcium"}, {"polarity": ["true"], "orig_sen": "In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. ", "drug2": "heme iron", "drug1": "calcium"}, {"polarity": ["false"], "orig_sen": "In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. ", "drug2": "heme iron", "drug1": "nonheme iron"}, {"polarity": ["true"], "orig_sen": "Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.", "drug2": "docetaxel", "drug1": "sunitinib"}, {"polarity": ["false"], "orig_sen": "This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.", "drug2": "sunitinib", "drug1": "sunitinib"}, {"polarity": ["false", "false"], "orig_sen": "This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.", "drug2": "docetaxel", "drug1": "sunitinib"}, {"polarity": ["false"], "orig_sen": "NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either sunitinib or docetaxel or both based on various sequential administrations. ", "drug2": "docetaxel", "drug1": "sunitinib"}, {"polarity": ["false"], "orig_sen": "Sunitinib exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas docetaxel arrested at S phase. ", "drug2": "docetaxel", "drug1": "Sunitinib"}, {"polarity": ["true"], "orig_sen": "Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. ", "drug2": "docetaxel", "drug1": "sunitinib"}, {"polarity": ["true"], "orig_sen": "When cells were exposed to docetaxel followed by sunitinib, synergism was observed. ", "drug2": "sunitinib", "drug1": "docetaxel"}, {"polarity": ["true"], "orig_sen": "The molecular basis of this synergism is that the signaling pathways that were initially activated by docetaxel exposure were efficiently suppressed by the subsequent exposure to sunitinib. ", "drug2": "sunitinib", "drug1": "docetaxel"}, {"polarity": ["false", "false"], "orig_sen": "Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.", "drug2": "docetaxel", "drug1": "Sunitinib"}, {"polarity": ["false", "false"], "orig_sen": "Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.", "drug2": "sunitinib", "drug1": "Sunitinib"}, {"polarity": ["true", "false"], "orig_sen": "Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.", "drug2": "sunitinib", "drug1": "docetaxel"}, {"polarity": ["false"], "orig_sen": "Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.", "drug2": "docetaxel", "drug1": "docetaxel"}, {"polarity": ["false"], "orig_sen": "Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.", "drug2": "sunitinib", "drug1": "sunitinib"}, {"polarity": ["false", "false"], "orig_sen": "Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.", "drug2": "docetaxel", "drug1": "sunitinib"}, {"polarity": ["false"], "orig_sen": "Distinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa.\r\n", "drug2": "methylglyoxal", "drug1": "piperacillin"}, {"polarity": ["false"], "orig_sen": "Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. ", "drug2": "carbenicillin", "drug1": "piperacillin"}, {"polarity": ["false"], "orig_sen": "Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. ", "drug2": "amikacin", "drug1": "piperacillin"}, {"polarity": ["false"], "orig_sen": "Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. ", "drug2": "ciprofloxacin", "drug1": "piperacillin"}, {"polarity": ["false"], "orig_sen": "Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. ", "drug2": "amikacin", "drug1": "carbenicillin"}, {"polarity": ["false"], "orig_sen": "Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. ", "drug2": "ciprofloxacin", "drug1": "carbenicillin"}, {"polarity": ["false"], "orig_sen": "Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. ", "drug2": "ciprofloxacin", "drug1": "amikacin"}, {"polarity": ["true"], "orig_sen": "Distinct and statistically significant synergism was observed between methylglyoxal and piperacillin by disc diffusion tests when compared with their individual effects. ", "drug2": "piperacillin", "drug1": "methylglyoxal"}, {"polarity": ["true"], "orig_sen": "Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.", "drug2": "carbenicillin", "drug1": "methylglyoxal"}, {"polarity": ["true"], "orig_sen": "Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.", "drug2": "amikacin", "drug1": "methylglyoxal"}, {"polarity": ["false"], "orig_sen": "Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.", "drug2": "amikacin", "drug1": "carbenicillin"}, {"polarity": ["false"], "orig_sen": "Protective effect of acetyl-l-carnitine and  alpha lipoic acid against the acute toxicity of diepoxybutane to human lymphocytes.", "drug2": "alpha lipoic acid", "drug1": "acetyl-l-carnitine"}, {"polarity": ["true"], "orig_sen": "(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.", "drug2": "alpha-lipoic acid", "drug1": "acetyl-l-carnitine"}, {"polarity": ["false"], "orig_sen": "[Influence of hemantane and doxycycline on MPTP-evoked behavior violations in C57BL/6 mice].\r\n", "drug2": "doxycycline", "drug1": "hemantane"}, {"polarity": ["false"], "orig_sen": "The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) ", "drug2": "hemantane", "drug1": "anti-parkinsonian drug"}, {"polarity": ["false"], "orig_sen": "The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) ", "drug2": "(2-adamantyl)hexamethylenimine", "drug1": "anti-parkinsonian drug"}, {"polarity": ["false"], "orig_sen": "The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) ", "drug2": "(2-adamantyl)hexamethylenimine", "drug1": "hemantane"}, {"polarity": ["false"], "orig_sen": "and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ", "drug2": "doxycycline", "drug1": "antibiotic drug"}, {"polarity": ["false"], "orig_sen": "and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ", "drug2": "1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine", "drug1": "antibiotic drug"}, {"polarity": ["false"], "orig_sen": "and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ", "drug2": "MPTP", "drug1": "antibiotic drug"}, {"polarity": ["false"], "orig_sen": "and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ", "drug2": "1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine", "drug1": "doxycycline"}, {"polarity": ["false"], "orig_sen": "and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ", "drug2": "MPTP", "drug1": "doxycycline"}, {"polarity": ["false"], "orig_sen": "and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ", "drug2": "MPTP", "drug1": "1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine"}, {"polarity": ["true"], "orig_sen": "Acute administration of hemantane or doxycycline failed to influence locomotion in mice, while their combination normalized motor activity. ", "drug2": "doxycycline", "drug1": "hemantane"}, {"polarity": ["true"], "orig_sen": "The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.\r\n", "drug2": "paclitaxel", "drug1": "dasatinib"}, {"polarity": ["false"], "orig_sen": "The effect of dasatinib, an inhibitor of Src and Abl kinases, on paclitaxel sensitivity was measured in ovarian cancer cells and HEY xenografts. ", "drug2": "paclitaxel", "drug1": "dasatinib"}, {"polarity": ["false"], "orig_sen": "The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by dasatinib and paclitaxel were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry. ", "drug2": "paclitaxel", "drug1": "dasatinib"}, {"polarity": ["true"], "orig_sen": "HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone. ", "drug2": "paclitaxel", "drug1": "dasatinib"}, {"polarity": ["true", "false", "false", "false", "false"], "orig_sen": "Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ", "drug2": "paclitaxel", "drug1": "dasatinib"}, {"polarity": ["false"], "orig_sen": "Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ", "drug2": "dasatinib", "drug1": "dasatinib"}, {"polarity": ["false"], "orig_sen": "Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ", "drug2": "dasatinib", "drug1": "paclitaxel"}, {"polarity": ["false", "false", "false"], "orig_sen": "Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ", "drug2": "paclitaxel", "drug1": "paclitaxel"}, {"polarity": ["false"], "orig_sen": "dasatinib + paclitaxel vs. ", "drug2": "paclitaxel", "drug1": "dasatinib"}, {"polarity": ["false"], "orig_sen": "The siRNA knockdown of p27(Kip1) decreased dasatinib- and paclitaxel-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017). ", "drug2": "paclitaxel", "drug1": "dasatinib"}, {"polarity": ["true"], "orig_sen": "Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. ", "drug2": "paclitaxel", "drug1": "dasatinib"}, {"polarity": ["true"], "orig_sen": "Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.", "drug2": "paclitaxel", "drug1": "dasatinib"}, {"polarity": ["false", "false", "false"], "orig_sen": "Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.\r\n", "drug2": "CCI-779", "drug1": "lenalidomide"}, {"polarity": ["false"], "orig_sen": "Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.\r\n", "drug2": "lenalidomide", "drug1": "lenalidomide"}, {"polarity": ["false"], "orig_sen": "Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.\r\n", "drug2": "lenalidomide", "drug1": "CCI-779"}, {"polarity": ["false"], "orig_sen": "Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.\r\n", "drug2": "CCI-779", "drug1": "CCI-779"}, {"polarity": ["true"], "orig_sen": "The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM.", "drug2": "CCI-779", "drug1": "lenalidomide"}, {"polarity": ["false"], "orig_sen": "Enhancement of humoral immune responses to inactivated Newcastle disease and avian influenza vaccines by oral administration of ginseng stem-and-leaf saponins in chickens.\r\n", "drug2": "ginseng stem-and-leaf saponins", "drug1": "avian influenza vaccines"}, {"polarity": ["false"], "orig_sen": "The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ", "drug2": "GSLS", "drug1": "ginseng stem-and-leaf saponins"}, {"polarity": ["false"], "orig_sen": "The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ", "drug2": "inactivated ND vaccines", "drug1": "ginseng stem-and-leaf saponins"}, {"polarity": ["false"], "orig_sen": "The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ", "drug2": "inactivated AI vaccines", "drug1": "ginseng stem-and-leaf saponins"}, {"polarity": ["false"], "orig_sen": "The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ", "drug2": "inactivated ND vaccines", "drug1": "GSLS"}, {"polarity": ["false"], "orig_sen": "The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ", "drug2": "inactivated AI vaccines", "drug1": "GSLS"}, {"polarity": ["false"], "orig_sen": "The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ", "drug2": "inactivated AI vaccines", "drug1": "inactivated ND vaccines"}, {"polarity": ["false"], "orig_sen": "In experiment 1, oral administration of GSLS at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with inactivated ND vaccine was evaluated. ", "drug2": "inactivated ND vaccine", "drug1": "GSLS"}, {"polarity": ["true"], "orig_sen": "In experiment 2, the same regimen of GSLS was administered to chickens inoculated with inactivated AI vaccines, and an enhanced serum antibody response to AI vaccination was also observed. ", "drug2": "inactivated AI vaccines", "drug1": "GSLS"}, {"polarity": ["false"], "orig_sen": "Considering the safety of GSLS, because no adverse effect was found throughout the experiments, GSLS may be a promising oral adjuvant to improve immunization in poultry.", "drug2": "GSLS", "drug1": "GSLS"}, {"polarity": ["false"], "orig_sen": "Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells.\r\n", "drug2": "imexon", "drug1": "dacarbazine"}, {"polarity": ["false"], "orig_sen": "We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.", "drug2": "DTIC", "drug1": "dacarbazine"}, {"polarity": ["false"], "orig_sen": "We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.", "drug2": "imexon", "drug1": "dacarbazine"}, {"polarity": ["false"], "orig_sen": "We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.", "drug2": "imexon", "drug1": "DTIC"}, {"polarity": ["false"], "orig_sen": "The effect of DTIC and imexon, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay). ", "drug2": "imexon", "drug1": "DTIC"}, {"polarity": ["false"], "orig_sen": "There was a >75% reduction in cellular glutathione and cysteine with imexon but not DTIC. ", "drug2": "DTIC", "drug1": "imexon"}, {"polarity": ["true"], "orig_sen": "Imexon and dacarbazine show additive effects in vitro but not in vivo in human A375 melanoma cells.", "drug2": "dacarbazine", "drug1": "Imexon"}, {"polarity": ["true"], "orig_sen": "Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.\r\n", "drug2": "herceptin", "drug1": "Lapatinib"}, {"polarity": ["true", "false", "false"], "orig_sen": "Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.", "drug2": "Herceptin", "drug1": "lapatinib"}, {"polarity": ["false"], "orig_sen": "Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.", "drug2": "lapatinib", "drug1": "lapatinib"}, {"polarity": ["false"], "orig_sen": "Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.", "drug2": "lapatinib", "drug1": "Herceptin"}, {"polarity": ["false"], "orig_sen": "Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.", "drug2": "Herceptin", "drug1": "Herceptin"}, {"polarity": ["false", "false"], "orig_sen": "We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). ", "drug2": "Herceptin", "drug1": "lapatinib"}, {"polarity": ["false"], "orig_sen": "We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). ", "drug2": "Herceptin", "drug1": "Herceptin"}, {"polarity": ["true"], "orig_sen": "In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC. ", "drug2": "Herceptin", "drug1": "lapatinib"}, {"polarity": ["true"], "orig_sen": "Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. ", "drug2": "lapatinib", "drug1": "Herceptin"}, {"polarity": ["false", "false"], "orig_sen": "Lapatinib may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.", "drug2": "Herceptin", "drug1": "Lapatinib"}, {"polarity": ["false"], "orig_sen": "Lapatinib may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.", "drug2": "Herceptin", "drug1": "Herceptin"}, {"polarity": ["false"], "orig_sen": "The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF, cross-reacting material 197 (CRM197). ", "drug2": "CRM197", "drug1": "cross-reacting material 197"}, {"polarity": ["false"], "orig_sen": "We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of CRM197 on these cells alone or in combination with anticancer agent. ", "drug2": "anticancer agent", "drug1": "CRM197"}, {"polarity": ["false"], "orig_sen": "CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. ", "drug2": "CRM197", "drug1": "CRM197"}, {"polarity": ["false", "true"], "orig_sen": "CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. ", "drug2": "doxorubicin", "drug1": "CRM197"}, {"polarity": ["true"], "orig_sen": "Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.\r\n", "drug2": "dexmedetomidine", "drug1": "Ephedrine"}, {"polarity": ["false"], "orig_sen": "The purpose of this study was to evaluate whether the psychostimulant drug ephedrine has any effect on dexmedetomidine-induced antinociception and locomotor inhibitor activity in mice in acute application.", "drug2": "dexmedetomidine", "drug1": "ephedrine"}, {"polarity": ["false", "false", "false"], "orig_sen": "saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ", "drug2": "dexmedetomidine", "drug1": "ephedrine"}, {"polarity": ["false"], "orig_sen": "saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ", "drug2": "ephedrine", "drug1": "ephedrine"}, {"polarity": ["false"], "orig_sen": "saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ", "drug2": "ephedrine", "drug1": "dexmedetomidine"}, {"polarity": ["false"], "orig_sen": "saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ", "drug2": "dexmedetomidine", "drug1": "dexmedetomidine"}, {"polarity": ["true"], "orig_sen": "In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. ", "drug2": "ephedrine", "drug1": "dexmedetomidine"}, {"polarity": ["false"], "orig_sen": "In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. ", "drug2": "dexmedetomidine", "drug1": "dexmedetomidine"}, {"polarity": ["false"], "orig_sen": "In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. ", "drug2": "dexmedetomidine", "drug1": "ephedrine"}, {"polarity": ["true"], "orig_sen": "At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine. ", "drug2": "ephedrine", "drug1": "dexmedetomidine"}, {"polarity": ["true"], "orig_sen": "We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.", "drug2": "ephedrine", "drug1": "dexmedetomidine"}, {"polarity": ["false"], "orig_sen": "We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.", "drug2": "dexmedetomidine", "drug1": "dexmedetomidine"}, {"polarity": ["false", "false"], "orig_sen": "We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.", "drug2": "analgesic", "drug1": "dexmedetomidine"}, {"polarity": ["false"], "orig_sen": "We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.", "drug2": "dexmedetomidine", "drug1": "ephedrine"}, {"polarity": ["false"], "orig_sen": "We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.", "drug2": "analgesic", "drug1": "ephedrine"}, {"polarity": ["false"], "orig_sen": "[Efficacy of fixed combination amlodipine/valsartan in hospitalized patients with hypertensive disease]", "drug2": "valsartan", "drug1": "amlodipine"}, {"polarity": ["false"], "orig_sen": "Efficacy and tolerability of fixed amlodipine/valsartan combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology. ", "drug2": "valsartan", "drug1": "amlodipine"}, {"polarity": ["false"], "orig_sen": "All patients had indications for antihypertensive therapy and were randomized either to fixed combination amlodipine/valsartan (n=43) or to therapy which corresponded to the hospital formulary (n=43). ", "drug2": "valsartan", "drug1": "amlodipine"}, {"polarity": ["false"], "orig_sen": "Rate of achievement of target BP with fixed combination amlodipine/valsartan (93%) was comparable with that on traditional therapy (90%). ", "drug2": "valsartan", "drug1": "amlodipine"}, {"polarity": ["true"], "orig_sen": "But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ", "drug2": "valsartan", "drug1": "amlodipine"}, {"polarity": ["false"], "orig_sen": "But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ", "drug2": "antihypertensive drugs", "drug1": "amlodipine"}, {"polarity": ["false"], "orig_sen": "But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ", "drug2": "antihypertensive drugs", "drug1": "valsartan"}, {"polarity": ["true"], "orig_sen": "We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.", "drug2": "valsartan", "drug1": "amlodipine"}, {"polarity": ["false"], "orig_sen": "We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.", "drug2": "antihypertensive drugs", "drug1": "amlodipine"}, {"polarity": ["false"], "orig_sen": "We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.", "drug2": "antihypertensive drugs", "drug1": "valsartan"}, {"polarity": ["false"], "orig_sen": "Ticagrelor (Brilinta)--better than clopidogrel (Plavix)", "drug2": "Brilinta", "drug1": "Ticagrelor"}, {"polarity": ["false"], "orig_sen": "Ticagrelor (Brilinta)--better than clopidogrel (Plavix)", "drug2": "clopidogrel", "drug1": "Ticagrelor"}, {"polarity": ["false"], "orig_sen": "Ticagrelor (Brilinta)--better than clopidogrel (Plavix)", "drug2": "Plavix", "drug1": "Ticagrelor"}, {"polarity": ["false"], "orig_sen": "Ticagrelor (Brilinta)--better than clopidogrel (Plavix)", "drug2": "clopidogrel", "drug1": "Brilinta"}, {"polarity": ["false"], "orig_sen": "Ticagrelor (Brilinta)--better than clopidogrel (Plavix)", "drug2": "Plavix", "drug1": "Brilinta"}, {"polarity": ["false"], "orig_sen": "Ticagrelor (Brilinta)--better than clopidogrel (Plavix)", "drug2": "Plavix", "drug1": "clopidogrel"}, {"polarity": ["false"], "orig_sen": "The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ", "drug2": "Brilinta", "drug1": "ticagrelor"}, {"polarity": ["false"], "orig_sen": "The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ", "drug2": "antiplatelet drug", "drug1": "ticagrelor"}, {"polarity": ["true"], "orig_sen": "The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ", "drug2": "aspirin", "drug1": "ticagrelor"}, {"polarity": ["false"], "orig_sen": "The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ", "drug2": "antiplatelet drug", "drug1": "Brilinta"}, {"polarity": ["true"], "orig_sen": "The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ", "drug2": "aspirin", "drug1": "Brilinta"}, {"polarity": ["false"], "orig_sen": "The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ", "drug2": "aspirin", "drug1": "antiplatelet drug"}, {"polarity": ["false"], "orig_sen": "It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. ", "drug2": "Plavix", "drug1": "clopidogrel"}, {"polarity": ["false"], "orig_sen": "It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. ", "drug2": "prasugrel", "drug1": "clopidogrel"}, {"polarity": ["false"], "orig_sen": "It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. ", "drug2": "Effient", "drug1": "clopidogrel"}, {"polarity": ["false"], "orig_sen": "It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. ", "drug2": "prasugrel", "drug1": "Plavix"}, {"polarity": ["false"], "orig_sen": "It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. ", "drug2": "Effient", "drug1": "Plavix"}, {"polarity": ["false"], "orig_sen": "It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. ", "drug2": "Effient", "drug1": "prasugrel"}, {"polarity": ["false"], "orig_sen": "Influence of piperine on ibuprofen induced antinociception and its pharmacokinetics.\r\n", "drug2": "ibuprofen", "drug1": "piperine"}, {"polarity": ["true", "false"], "orig_sen": "In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. ", "drug2": "ibuprofen", "drug1": "piperine"}, {"polarity": ["false"], "orig_sen": "In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. ", "drug2": "acetic acid", "drug1": "piperine"}, {"polarity": ["false"], "orig_sen": "In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. ", "drug2": "acetic acid", "drug1": "ibuprofen"}, {"polarity": ["false"], "orig_sen": "In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. ", "drug2": "ibuprofen", "drug1": "ibuprofen"}, {"polarity": ["false"], "orig_sen": "In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. ", "drug2": "ibuprofen", "drug1": "acetic acid"}, {"polarity": ["true"], "orig_sen": "Ibuprofen plasma concentration was also increased when it was administered with piperine. ", "drug2": "piperine", "drug1": "Ibuprofen"}, {"polarity": ["true"], "orig_sen": "The synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen. ", "drug2": "piperine", "drug1": "ibuprofen"}, {"polarity": ["false"], "orig_sen": "The synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen. ", "drug2": "ibuprofen", "drug1": "ibuprofen"}, {"polarity": ["false"], "orig_sen": "The synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen. ", "drug2": "ibuprofen", "drug1": "piperine"}, {"polarity": ["true"], "orig_sen": "From this study it can be concluded that piperine can be used as a bioenhancer along with ibuprofen.", "drug2": "ibuprofen", "drug1": "piperine"}]